MicrobiologybioRxiv
Bcr-Abl tyrosine kinase inhibitor imatinib as a potential drug for COVID-19
N. S. Mulgaonkar, H. Wang, S. Mallawarachchi…·S. Fernando
This paper reports that imatinib, an FDA-approved Bcr-Abl inhibitor, inhibits SARS-CoV-2 and other coronaviruses by blocking viral membrane fusion, suggesting its potential as a repurposed drug for COVID-19.
DOI 10.1080/07391102.2022.2045221